Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 30 | Vintage Vibes

All that You Really want to Be familiar with Arimidex

Arimidex (Anastrozole) is a major area of strength for an inhibitor reliably used to direct estrogen levels in both sensible and lifting loads settings. At first expected to oversee chest most harmful developments in postmenopausal women, Arimidex ...

USA Today Sports Media Group

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

International Business Times

AstraZeneca shares tumble after reports China unit is linked to insurance fraud

Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Kiplinger

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

StockNews.com

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage

Demand for the popular weight loss and diabetes drugs has spiked dramatically in recent years

The Independent UK

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Cheap Mexican Drugs Forcing Canadian Cartels to Export Meth to Other Countries

Canadian manufacturers of methamphetamine are being pushed to begin selling their product in foreign markets after being unable to compete with cheaper product from Mexico circulating in their home market.

Latin Times

More than half of WA pharmacies choosing not to stock vapes, survey shows

Exclusive: Uncertainty over regulations and discomfort over stocking a product not evaluated by drugs regulator among reasons given

The Guardian - AU

AstraZeneca ‘said it could cut UK jobs’ if biodiversity drug levy is introduced

Biotech giant’s alleged comments come as world leaders at Cop16 discuss how to share benefits from genetic code discoveries fairly

The Guardian - UK

Missouri Seeks to Block Access to Abortion Pill Because It's Stopping Teens from Getting Pregnant

Fewer teenage pregnancies means a population loss for the states, as well as "diminishment of political representation and loss of federal funds."

Latin Times

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

StockNews.com

US series with ‘most agonising cliffhanger’ in years is finally returning

Fans have been waiting more than two years for show to return

The Independent UK

Sanofi confirms €16 billion sale of painkiller Doliprane to US investors

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

Radio France Internationale

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

France Bristles At Painkiller Maker's Sale To US Fund

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal marks a loss of sovereignty over key medications.

The Guardian - UK

France warns US buyer of Sanofi division of penalties for shifting production abroad

Private equity firm CD&R revealed to be in exclusive talks to buy 50% stake in consumer healthcare arm Opella

International Business Times

Sanofi Pursues Sale Of Painkiller After Political Controversy

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

The Independent UK

Britons most likely in Europe to turn to unregulated alternative therapies

UK consumers are most likely patients in Europe likely to seek health advice from social media, poll suggests

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Small-Cap Biotech Stocks With Game-Changing Potential

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high growth. Thus, investing in fundamentally strong small-cap stocks Esperion Therapeutics (ESPR), Innoviva, Inc. (INVA), and SIGA Technologies (SIGA) could be significantly rewarding. Read on….

International Business Times

Visionary Marc DeValera: A Story of a Miraculous Discovery Turning into a Respiratory Treatment Revolution

Passionate about returning Big Pharma's power to the people, Marc DeValera, founder of MLFD-MedTech Inc., developed 3 essential oils using a Mesh Nebulizer, an all-natural alternative to respiratory treatments.

Evening Standard

Best Cytoplan supplements for women in midlife

Research has found that 40 per cent of women over the age of 45 have a chronic health condition

The Guardian - UK

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Radio France Internationale

France could block sale of 'best-selling' drug if production doesn't stay local

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical company Sanofi to a US private equity firm if it cannot guarantee that its production of paracetamol, under the name Doliprane, remains in France.

International Business Times

Painkiller Sale Plan To US Gives France Major Headache

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

The Guardian - UK

There’s an elephant in the room at Keir Starmer’s big investment summit: Brexit

We need a salvage operation to fix the problems this created. Otherwise, how else will we attract global investment, asks Labour MP Stella Creasy

1 … 29 30 31 32

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.